FS.COM
19.6.2020 10:02:08 CEST | Business Wire | Press release
FS.COM , a high-speed communication product and solution provider for data centers, enterprises, and telecom networks, collaborated with US Conec, a leader in providing passive components for high density optical interconnects, to supply MTP® brand cable assembly products for high density data center applications.
With the ever-growing demands on high speed networks, MTP® cabling systems are required to provide more connections in limited space applications. “Each FS MTP® cable uses US Conec's MTP® connectors to ensure stable and highly effective interconnections of MTP® cabling infrastructure in data center environments. US Conec's MTP® connectors are recognized as the industry leading high density cabling solution for low insertion loss, excellent optical performance and space saving advantages,” said Daniel Xiang, CEO of FS.COM. “In addition to MTP® cabling products, FS.COM has introduced ancillary products from the MTP® family including MTP® cleaners, MTP® adapters and field tools for MTP® PRO connector.”
MTP® cleaners
- Clean ferrules of MT based connectors with simple push for cabling assemblies and field installation
MTP® adapters
- Compatible with all US Conec MTP® brand connectors from 4 to 72 fibers for coupling and debris protection
Field tools for MTP® PRO connector
- Simple change of MTP® PRO cable polarity and pins in less than a minute
“We are excited to partner with FS.COM to deliver optical technology and connectivity solutions that will drive the next generation of communications infrastructure worldwide,” states Joe Graham, President of US Conec. “FS.COM has demonstrated strong market access and we feel that together we can deliver superior value to our collective customer base.”
MTP® is a registered trademark of US Conec Ltd.
About US Conec
US Conec is a global leader in the design and development of high-density optical interconnects. With nearly 30 years of innovative experience, the company provides industry leading components for data center and enterprise structured cabling, public networks, on-board optical interconnects, industrial and military markets worldwide. Key product developments include single-mode and multimode MT-style and custom multi-fiber ferrules, MTP® brand MPO connectors, MXC® connectors, PRIZM® LightTurn® and PRIZM® MT lensed ferrule technology, ELiMENT™ single fiber connector solutions, IBC™ brand fiber optic cleaning solutions, termination equipment for multi-fiber interconnects, and high precision optical packaging components. US Conec is headquartered in Hickory, North Carolina, and is an equity venture of three leading communication technology companies—Corning Optical Communications, Fujikura, and NTT-AT.
About FS.COM
FS.COM is a high-speed communication product and solution provider for connecting and securing global data center, enterprise, and telecom networks. FS.COM is dedicated to fulfilling product systems and tailoring project solutions for IT professionals with immediate services by developing its talents, labs and local service center. Through continuous technology innovation and brand partnership, FS products and solutions have served more than 300,000+ customers in over 200 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200619005075/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom